Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 586.36% and ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Most U.S. patients are covered by health insurance and would likely pay less for the drugs. Novo and rival Eli Lilly, which makes the weight loss drug Zepbound, have filed a flurry of lawsuits against ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

The company shipped some 750 vials of testosterone to customers who had instead ordered tirzepatide, the active ingredient in ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

GLP-1 weight loss medications like Ozempic and Wegovy have become blockbuster ... Other pharmaceutical companies are also entering the race to develop oral GLP-1 treatments. Eli Lilly is testing an ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...